

## Bibliographie

Al-Salama ZT. Imlifidase: First Approval. *Drugs*. 2020 Nov;80(17):1859-1864.

Benkhoucha M, Molnarfi N, Santiago-Raber ML, Weber MS, Merkler D, Collin M, Lalive PH. IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis. *J Neuroinflammation*. 2012 Sep 3;9:209.

Berge A, Björck L. Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins. *J Biol Chem*. 1995 Apr 28;270(17):9862-7.

Cassuto J, Babu S, Laskowski I. The survival benefit of kidney transplantation in the setting of combined peripheral arterial disease and end-stage renal failure. *Clin Transplant*. 2016 May;30(5):545-55.

Collin M, Olsén A. EndoS, a novel secreted protein from *Streptococcus pyogenes* with endoglycosidase activity on human IgG. *EMBO J*. 2001 Jun 15;20(12):3046-55.

Couzi L, Malvezzi P, Amrouche L, Anglicheau D, Blanche G, Caillard S, Freist M, Guidicelli GL, Kamar N, Lefaucheur C, Mariat C, Koenig A, Noble J, Thaumat O, Thierry A, Taupin JL, Bertrand D. Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines. *Transpl Int*. 2023 Jun 28;36:11244.

Cunningham MW. Pathogenesis of group A streptococcal infections. *Clin Microbiol Rev*. 2000 Jul;13(3):470-511.

EMA Idefirix, INN-implifidase summary of product characteristics n.d.:1–28. Available at: [https://www.ema.europa.eu/en/documents/product-information/idefirix-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/idefirix-epar-product-information_en.pdf). Accessed 5/31/2022.

Falugi F, Kim HK, Missiakas DM, Schneewind O. Role of protein A in the evasion of host adaptive immune responses by *Staphylococcus aureus*. *mBio*. 2013 Aug 27;4(5):e00575-13.

Ge S, Chu M, Choi J, Louie S, Vo A, Jordan SC, Toyoda M. Imlifidase Inhibits HLA Antibody-mediated NK Cell Activation and Antibody-dependent Cell-mediated Cytotoxicity (ADCC) In Vitro. *Transplantation*. 2020 Aug;104(8):1574-1579.

Haller MC, Kammer M, Oberbauer R. Dialysis vintage and outcomes in renal transplantation. *Nephrol Dial Transplant*. 2019 Apr 1;34(4):555-560.

Holder IA, Wheeler R. Experimental studies of the pathogenesis of infections owing to *Pseudomonas aeruginosa*: elastase, an IgG protease. *Can J Microbiol.* 1984 Sep;30(9):1118-24.

Huang, E., Jordan, S.C. Imlifidase as a Potential Treatment for Antibody-Mediated Rejection. *Curr Transpl Rep* 8, 157–161 (2021).

Järnum S, Bockermann R, Runström A, Winstedt L, Kjellman C. The Bacterial Enzyme IdeS Cleaves the IgG-Type of B Cell Receptor (BCR), Abolishes BCR-Mediated Cell Signaling, and Inhibits Memory B Cell Activation. *J Immunol.* 2015 Dec 15;195(12):5592-601.

Jordan SC, Lorant T, Choi J. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. *N Engl J Med.* 2017 Oct 26;377(17):1693-4.

Jordan SC, Legendre C, Desai NM, Lorant T, Bengtsson M, Lonze BE, Vo AA, Runström A, Laxmyr L, Sjöholm K, Schiödt Å, Sonesson E, Wood K, Winstedt L, Kjellman C, Montgomery RA. Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes). *Transplantation.* 2021 Aug 1;105(8):1808-1817

Kihlberg BM, Collin M, Olsén A, Björck L. Protein H, an antiphagocytic surface protein in *Streptococcus pyogenes*. *Infect Immun.* 1999 Apr;67(4):1708-14.

Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK; Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *JAMA.* 2007 Oct 17;298(15):1763-71.

Klontz EH. Chop-Chop: The Future of Bacterial Enzymes in Transfusion Medicine. *Transfus Med Rev.* 2022 Oct;36(4):246-251.

Leffell MS. The calculated panel reactive antibody policy: an advancement improving organ allocation. *Curr Opin Organ Transplant.* 2011 Aug;16(4):404-9.

Lorant T, Bengtsson M, Eich T, Eriksson BM, Winstedt L, Järnum S, Stenberg Y, Robertson AK, Mosén K, Björck L, Bäckman L, Larsson E, Wood K, Tufveson G, Kjellman C. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. *Am J Transplant.* 2018 Nov;18(11):2752-2762.

Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence- Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019 Jun;34(3):171-354.

Pinelli DF, Zachary AA, Friedewald JJ, Gjertson DW, Evans MA, Chatroop EN, Leffell MS, Vo AA, Jordan SC, Montgomery RA, Tambur AR. Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy. Am J Transplant. 2019 Feb;19(2):381-390.

Shin JI, Geetha D, Szpirt WM, Windpessl M, Kronbichler A. Anti-glomerular basement membrane disease (Goodpasture disease): From pathogenesis to plasma exchange to IdeS. Ther Apher Dial. 2022 Feb;26(1):24-31.

Sidorin EV, Solov'eva TF. IgG-binding proteins of bacteria. Biochemistry (Mosc). 2011 Mar;76(3):295-308.

Soveri I, Mölne J, Uhlin F, Nilsson T, Kjellman C, Sonesson E, Segelmark M. The IgG-degrading enzyme of *Streptococcus pyogenes* causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti- glomerular basement membrane disease. Kidney Int. 2019 Nov;96(5):1234-1238.

Tambur AR, Wiebe C. HLA Diagnostics: Evaluating DSA Strength by Titration. Transplantation. 2018 Jan;102(1S Suppl 1):S23-S30.

Tolo K, Helgeland K. Fc-binding components: a virulence factor in *Actinobacillus actinomycetemcomitans*? Oral Microbiol Immunol. 1991 Dec;6(6):373-7.

Uhlin F, Szpirt W, Kronbichler A, Bruchfeld A, Soveri I, Rostaing L, Daugas E, Lionet A, Kamar N, Rafat C, Mysliveček M, Tesař V, Fernström A, Kjellman C, Elfving C, McAdoo S, Mölne J, Bajema I, Sonesson E, Segelmark M. Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies *in vivo* in Severe Kidney Disease: An Open-Label Phase 2a Study. J Am Soc Nephrol. 2022 Apr;33(4):829-838.

Vincent B, von Pawel-Rammingen U, Björck L, Abrahamson M. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry. 2004 Dec 14;43(49):15540-9.

von Pawel-Rammingen U, Johansson BP, Björck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 2002 Apr 2;21(7):1607-15.

Wenig K, Chatwell L, von Pawel-Rammingen U, Björck L, Huber R, Sonderrmann P. Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. *Proc Natl Acad Sci U S A*. 2004 Dec 14;101(50):17371-6

Winstedt L, Järnum S, Nordahl EA, Olsson A, Runström A, Bockermann R, Karlsson C, Malmström J, Palmgren GS, Malmqvist U, Björck L, Kjellman C. Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic Opportunity. *PLoS One*. 2015 Jul 15;10(7):e0132011.

Yang R, Otten MA, Hellmark T, Collin M, Björck L, Zhao MH, Daha MR, Segelmark M. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. *Nephrol Dial Transplant*. 2010 Aug;25(8):2479-86.